Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockView Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Samsrita Labs Ltd (SAMSRITA) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Samsrita Labs Limited, formerly Dr Habeebullah Life Sciences Limited, is engaged in the bio-pharma sector focusing on drug discovery, stem cell therapy, and molecular diagnostics. The company has transitioned from its initial focus on stem cell hospitals to include biopharma activities, emphasized by its historical changes in main business objects to incorporate advanced drug discovery and biotechnology research. It has a strategic collaborative agreement with Krisani Bio Sciences and the Centre for Liver Research and Diagnostics to advance research in NASH and Wilson Disease through revenue-sharing partnerships. The company focuses on affordable healthcare, reflecting its dedication to advancing RNAi therapeutics, biomarker discovery, and other niche biotechnologies. Krisani Bio Sciences transformed from a subsidiary to an associate company, altering Samsrita Labs' ownership stake and highlighting strategic restructuring in shareholding.
Over the past 52 weeks, Samsrita Labs Ltd has traded between a low of ₹10.15 and a high of ₹25.27. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Samsrita Labs Ltd has a market capitalization of approximately 26.18. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Samsrita Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -3.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 26.18 Cr, Samsrita Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Samsrita Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Samsrita Labs Ltd is -3.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Samsrita Labs held its 30th AGM on August 10, 2026, via video conferencing, with 70 members attending.
Bearish
1
Neutral
12
Bullish
1
Bearish
1
Neutral
44
Bullish
1
Bearish
0
Neutral
32
Bullish
0
Bearish
1
Neutral
12
Bullish
1
Bearish
1
Neutral
12
Bullish
1
Bearish
0
Neutral
32
Bullish
0
Bearish
0
Neutral
32
Bullish
0
Bearish
0
Neutral
32
Bullish
0
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
11.87 | 29 Cr | 11.61 | 0.27 | 0.00 | 2.26 | 3.18 | 1.70 | ||
85.00 | 28 Cr | 23.51 | 2.18 | 0.00 | 9.06 | 9.88 | 3.61 | ||
37.00 | 28 Cr | -67.41 | 0.00 | 0.00 | 36.33 | -3.29 | -1.93 | ||
13.00 | 26 Cr | 21.47 | 0.97 | 0.00 | 4.52 | 6.35 | 4.09 | ||
11.21 | 26 Cr | -3.00 | 2.23 | 0.00 | -69.43 | -64.75 | -60.71 | ||
2.53 | 19 Cr | -11.91 | 2.29 | 0.00 | -19.73 | -2.32 | -1.12 | ||
12.90 | 18 Cr | 11.95 | 0.26 | 0.00 | 2.51 | 5.93 | 1.79 | ||
| Median: 7 Co. | — | 12.90 | 26 Cr | 11.61 | 0.97 | 0.00 | 2.51 | 3.18 | 1.70 |
Samsrita Labs Limited, formerly Dr Habeebullah Life Sciences Limited, is engaged in the bio-pharma sector focusing on drug discovery, stem cell therapy, and molecular diagnostics.
The company has transitioned from its initial focus on stem cell hospitals to include biopharma activities, emphasized by its historical changes in main business objects to incorporate advanced drug discovery and biotechnology research.
It has a strategic collaborative agreement with Krisani Bio Sciences and the Centre for Liver Research and Diagnostics to advance research in NASH and Wilson Disease through revenue-sharing partnerships.
The company focuses on affordable healthcare, reflecting its dedication to advancing RNAi therapeutics, biomarker discovery, and other niche biotechnologies.
Krisani Bio Sciences transformed from a subsidiary to an associate company, altering Samsrita Labs' ownership stake and highlighting strategic restructuring in shareholding.
Healthcare Services
Healthcare Service Provider
26 Cr
Low Risk
-3.0
63.4
—
2.2
25.27
10.15
Sales CAGR
Profit CAGR
ROE
ROCE
